Dillon & Associates’s Pacira BioSciences PCRX Stock Holding History

Dillon & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,749	Closed	-$240K	–	80
2023 Q3	$240K	Sell	7,749 -7,204	-48%	-$260K	0.05%	74
2023 Q2	$598K	Sell	14,953 -26,735	-64%	-$1.11M	0.11%	59
2023 Q1	$1.71M	Sell	41,688 -230	-0.5%	-$9.15K	0.34%	46
2022 Q4	$1.64M	Sell	41,918 -1,460	-3%	-$71K	0.35%	48
2022 Q3	$2.3M	Buy	43,378 +11,534	+36%	+$641K	0.53%	40
2022 Q2	$1.85M	Buy	31,844 +28,759	+932%	+$1.88M	0.42%	41
2022 Q1	$234K	Buy	+3,085	New	+$206K	0.04%	72

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Dillon & Associates's PCRX Position: Q4 2023 in Review

Dillon & Associates sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 7,749 shares — an estimated $240K sold.

Dillon & Associates first reported a position in PCRX in Q1 2022 and held it in 7 quarters. The position peaked at $2.3M in Q3 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Dillon & Associates reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Dillon & Associates sold 7,749 Pacira BioSciences shares in Q4 2023, an estimated $240K.
Dillon & Associates first reported a position in Pacira BioSciences in Q1 2022 and held it in 7 quarters.
Dillon & Associates's Pacira BioSciences position peaked at $2.3M in Q3 2022.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Dillon & Associates's 13F filing for Q4 2023, filed 8 Feb 2024.